Onconova Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023 at 04:05 pm EDT
Share
Onconova Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 0.057 million compared to USD 0.057 million a year ago. Net loss was USD 4.25 million compared to USD 4.02 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 0.19 a year ago.
For the six months, sales was USD 0.113 million compared to USD 0.113 million a year ago. Net loss was USD 10.03 million compared to USD 8.15 million a year ago. Basic loss per share from continuing operations was USD 0.48 compared to USD 0.39 a year ago.
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclibâs mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).